‌

US Patent 10822412 Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy

Patent 10822412 was granted and assigned to Lentigen on November, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

Lentigen

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

108224120

Date of Patent

November 3, 2020

Patent Application Number

165843080

Date Filed

September 26, 2019

Patent Citations Received

‌

US Patent 11878052 Compositions and methods for treating cancer with anti-CD22 immunotherapy

‌

US Patent 11242389 Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy

Patent Primary Examiner

‌

Janet L Epps-Smith

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10822412 Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API